长江健康（002435）投资者索赔案持续推进

Core Viewpoint - The article discusses ongoing legal actions against Changjiang Health (002435) due to alleged false statements and failure to disclose significant financial issues, leading to investor claims for compensation [1][6]. Group 1: Allegations of Financial Misconduct - Changjiang Health is accused of failing to timely disclose non-operating fund occupation by related parties, with a total of 655 million yuan involved, which is 1.27% of the company's net assets as of 2020 [2][7]. - The company has not reported the ongoing fund occupation, which had an outstanding balance of 3.558 billion yuan as of April 30, 2024, with significant amounts occupied in various periods, reaching up to 79.01% of net assets in 2022 [2][7]. - There were also failures in accounting for liabilities related to commercial acceptance bills and financing leases, resulting in understated liabilities in multiple financial reports, totaling 758 million yuan to 1.353 billion yuan across different periods [3][8]. Group 2: Disclosure Failures - Changjiang Health allegedly did not disclose a significant guarantee involving a 500 million yuan bank acceptance bill, which was backed by a time deposit and constituted 10.75% of the company's audited net assets for 2022 [4][9]. - The company failed to follow necessary shareholder approval procedures for this guarantee, which is a violation of securities laws requiring timely disclosure of such significant events [4][9]. Group 3: Legal Actions and Investor Claims - Investors who purchased Changjiang Health shares between January 5, 2021, and April 30, 2024, and sold or continued to hold them after April 30, 2024, are eligible to initiate claims for compensation [10].